scholarly journals Increased serum levels of mBDNF in women with minimal and mild endometriosis have no predictive power for the disease

2017 ◽  
Vol 243 (1) ◽  
pp. 50-56 ◽  
Author(s):  
Alexandra Perricos ◽  
Kazem Ashjaei ◽  
Heinrich Husslein ◽  
Katharina Proestling ◽  
Lorenz Kuessel ◽  
...  
Keyword(s):  
Laparoscopic Surgery ◽  
Pelvic Pain ◽  
Neurotrophic Factor ◽  
Serum Levels ◽  
Brain Derived Neurotrophic Factor ◽  
Stage I ◽  
Cycle Phase ◽  
Mature Brain ◽  
Potential Biomarker ◽  
The Difference

The objective of our pilot clinical, prospective study was to determine the serum levels of mature brain-derived neurotrophic factor, in of women with endometriosis and controls and explore whether mature brain-derived neurotrophic factor is a potential biomarker for the disease. The patients were selected from the Endometriosis Marker Austria prospective cohort study conducted at the tertiary referral certified Endometriosis Center of the Medical University of Vienna. All women underwent laparoscopic surgery because there was a suspicion of endometriosis, or the women had pelvic pain, adnexal cysts, unexplained infertility, or uterine fibroids. Our main outcome parameter was total levels of mature brain-derived neurotrophic factor in serum, measured using ELISA. Our results show that serum levels of mature brain-derived neurotrophic factor are significantly higher in women with endometriosis compared to women without endometriosis. The mean serum protein levels are significantly higher in women with rAFS stage I and II endometriosis, whereas no difference was found in women with stage III and IV endometriosis and controls. Postoperative follow-up at 6–10 weeks revealed that surgical intervention leads to equilibration of the levels of secreted mature brain-derived neurotrophic factor between women with and without endometriosis. The difference between serum mature brain-derived neurotrophic factor levels of women with endometriosis compared to women without endometriosis is independent of menstrual cycle phase and overall self-reported pelvic pain. ROC-curve analysis showed that, the mature brain-derived neurotrophic factor is not a useful biomarker for endometriosis. In conclusion, although women with stage I and II endometriosis have increased levels of mature brain-derived neurotrophic factor in serum compared to controls, the difference is not predictive for the disease. Impact statement Endometriosis is a disease that can have a significant impact on the quality of life of affected women. The gold standard for diagnosis to this day remains visualization through laparoscopic surgery with histological verification. Current studies are attempting to find a biomarker with high sensitivity and specificity, which would bypass the surgery-associated risks and would significantly reduce costs. In an attempt to elucidate whether mature serum BDNF can serve as diagnostic marker for the disease, we compared the levels of the protein in women with endometriosis to endometriosis-free controls. While our results showed that serum concentrations of the mature protein were significantly higher in women with endometriosis, we did not find this marker to have the sensitivity or specificity needed in order to allow a reliable diagnosis.

A positive correlation between serum levels of mature brain-derived neurotrophic factor and negative symptoms in schizophrenia

2014 ◽  
Vol 215 (2) ◽  
pp. 268-273 ◽  
Author(s):  
Tomihisa Niitsu ◽  
Tamaki Ishima ◽  
Taisuke Yoshida ◽  
Tasuku Hashimoto ◽  
Daisuke Matsuzawa ◽  
...  
Keyword(s):  
Neurotrophic Factor ◽  
Negative Symptoms ◽  
Serum Levels ◽  
Brain Derived Neurotrophic Factor ◽  
Positive Correlation ◽  
Mature Brain

scholarly journals Brain-Derived Neurotrophic Factor and Its Serum Levels in Schizophrenic Patients

Folia Medica ◽  
2014 ◽  
Vol 56 (1) ◽  
pp. 20-23 ◽  
Author(s):  
Yvetta A. Koeva ◽  
Stefan T. Sivkov ◽  
Valentin H. Akabaliev ◽  
Roumiana Y. Ivanova ◽  
Tania I. Deneva ◽  
...  
Keyword(s):  
Neurotrophic Factor ◽  
Statistical Significance ◽  
Serum Levels ◽  
Brain Derived Neurotrophic Factor ◽  
Control Group ◽  
Significant Difference ◽  
Schizophrenic Patients ◽  
The Difference ◽  
Student’S T ◽  
Serum Bdnf

ABSTRACT INTRODUCTION: Neurotrophins have an important role in regulating the development and maintenance of the peripheral and central nervous systems’ function. Thus, the neurotrophin hypothesis of schizophrenia has postulated that the changes in the brain of schizophrenic patients are the result of disturbances of developing processes involving these molecules. AIM: We analyse in the present study the changes in the serum levels of brain-derived neurotrophic factor (BDNF) in schizophrenic patients as possible epiphenomena of underlying alterations of the neurotrophic factor in central nervous system, reflecting its role in the pathophysiology of schizophrenia. PATIENTS AND METHODS: Twenty-one schizophrenic patients satisfying the DSM-IV criteria for diagnosis of schizophrenia were enrolled in the study. The control group consisted of 28 age-matched mentally healthy subjects. Serum BDNF levels were determined in patients and normal controls using ELISA (Chemicon International, USA & Canada). The data were analyzed statistically with Student’s t- test in SPSS 9.0. RESULTS: The serum BDNF levels were lower in the schizophrenic patients than in the control subjects, reaching statistically significant difference (t = 2.72, p = 0.009). Female patients had lower serum BDNF levels than the male patients but the difference fell short of statistical significance (t = 0.1, p = 0.9). CONCLUSIONS: The BDNF reduction in serum indicates a potential deficit in neurotrophic factor release in patients with schizophrenia and support the concept that BDNF might be associated with schizophrenia

Plasma brain-derived neurotrophic factor in women with pelvic pain: a potential biomarker for endometriosis?

2017 ◽  
Vol 11 (4) ◽  
pp. 313-317 ◽  
Author(s):  
Ana L Rocha ◽  
Erica L Vieira ◽  
Márcia C Ferreira ◽  
Laura M Maia ◽  
Antonio L Teixeira ◽  
...  
Keyword(s):  
Pelvic Pain ◽  
Neurotrophic Factor ◽  
Brain Derived Neurotrophic Factor ◽  
Potential Biomarker

scholarly journals Decreased Serum Levels of Mature Brain-Derived Neurotrophic Factor (BDNF), but Not Its Precursor proBDNF, in Patients with Major Depressive Disorder

PLoS ONE ◽  
2012 ◽  
Vol 7 (8) ◽  
pp. e42676 ◽  
Author(s):  
Taisuke Yoshida ◽  
Masatomo Ishikawa ◽  
Tomihisa Niitsu ◽  
Michiko Nakazato ◽  
Hiroyuki Watanabe ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Neurotrophic Factor ◽  
Serum Levels ◽  
Brain Derived Neurotrophic Factor ◽  
Major Depressive ◽  
Mature Brain

Brain-derived neurotrophic factor is associated with coronary macrophage infiltrates in patients with acute coronary syndrome

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
R.A Montone ◽  
M Camilli ◽  
M Russo ◽  
M Del Buono ◽  
F Gurguglione ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Neurotrophic Factor ◽  
Serum Levels ◽  
Brain Derived Neurotrophic Factor ◽  
C Reactive Protein ◽  
St Segment Elevation ◽  
Protein Levels ◽  
Reactive Protein ◽  
Coronary Syndrome ◽  
St Segment

Abstract Background Brain-derived neurotrophic factor (BDNF) is a neurotrophine that plays a key role in the regulation of both central and peripheral nervous system. Moreover, BDNF is secreted in multiple tissues and exerts systemic, autocrine, and paracrine effects in the cardiovascular system. Of importance, BDNF expression was enhanced in macrophages and smooth muscle cells in atherosclerotic coronary arteries and may be involved in thrombus formation. Thus, BDNF has been suggested as an important link between inflammation and thrombosis, potentially involved in the pathogenesis of acute coronary syndrome (ACS). Purpose In our study we aimed at assessing serum levels of BDNF in patients with ACS, evaluating differences according to clinical presentation [ST-segment elevation myocardial infarction (STEMI) vs. Non-ST-segment elevation ACS (NSTE-ACS)]. Moreover, we assessed the presence of optical coherence (OCT)-defined macrophage infiltrates (MØI) in the culprit vessel of ACS patients and evaluated their relationship with BDNF levels. Methods ACS patients were prospectively selected. Blood samples were collected at admission and serum levels of BDNF were subsequently assessed. Presence of OCT-defined MØI along the culprit vessel was assessed. Results 166 ACS patients were enrolled [mean age 65.3±11.9 years, 125 (75.3%) male, 109 STEMI, 57 NSTE-ACS]. Serum levels of BDNF were higher among STEMI patients compared with NSTE-ACS [median (IQR) 2.48 pg/mL (1.54–3.34) vs. 2.12 pg/mL (1.34–2.47), p=0.007], while C-reactive protein levels did not differ between the two groups. OCT assessment was performed in 53 patients and MØI were detected in 27 patients. Of importance, patients with MØI in the culprit vessel had higher levels of BDNF compared with patients without MØI [median (IQR) 2.23 pg/mL (1.38–2.53) vs. 1.41 pg/mL (0.93–2.07), p=0.023], while C-reactive protein levels did not differ between the two groups. Of note, at multivariate regression analysis BDNF levels were independent predictor of MØI [OR: 2.20; 95% CI (1.02–4.74), p=0.043]. Conclusions Serum levels of BDNF may reliable identify the presence of local macrophage inflammatory infiltrates in patients with ACS. Moreover, BDNF levels are higher in patients with STEMI compared with NSTE-ACS. Taken together, these data suggest that BDNF may represent an interesting link between local inflammatory activation and enhanced thrombosis in ACS. BDNF serum levels Funding Acknowledgement Type of funding source: None

Brain-derived neurotrophic factor serum levels in heroin-dependent patients after 26weeks of withdrawal

2016 ◽  
Vol 65 ◽  
pp. 150-155 ◽  
Author(s):  
Kai Zhang ◽  
Haifeng Jiang ◽  
Qiaoyang Zhang ◽  
Jiang Du ◽  
Yuan Wang ◽  
...  
Keyword(s):  
Neurotrophic Factor ◽  
Serum Levels ◽  
Brain Derived Neurotrophic Factor
Sign in / Sign up

Export Citation Format

Share Document